Omega-3 fatty acids and sublingual immunotherapy have a considerable interest in the potential therapeutic value in asthmatic patients. The aim of the study was to compare the efficacy of omega-3 fatty acids and sublingual immunotherapy in treating patients with bronchial asthma and evaluate the value of IL17A as a marker for effective treatment. The effect on asthma control test (ACT), peak expiratory flow rate (PEFR), forced expiratory volume in the first second (FEV1) and serum interleukin 17A (IL17A) in patients with mild to moderate persistent asthma were measured. A total of 48 patients were enrolled and divided into two groups. Group A included 24 patients treated with sublingual immunotherapy for 6 months and group B, 24 patients given omega-3 fatty acids for 3 months. Serum level of IL17A was measured by Enzyme linked immunosorbent assay (ELISA). A statistically significant difference was demonstrated in each parameter between before and after treatment (p< 001, for each). Comparison between omega-3 fatty acids and sublingual immunotherapy as regards ACT, PEFR, and FEV1and IL17A showed that omega-3 fatty acids treatment was better than sublingual immunotherapy in decreasing IL17A, but both were effective in decreasing PEFR, FEV1 and ACT. In conclusion, administration of omega-3 fatty acids and sublingual immunotherapy are promising in management of asthma.